Form 4: Amphastar Exec's Future Stock Sale for Tax Liability

Amphastar Pharmaceuticals Senior EVP Zhou Rong filed a Form 4 disclosing a future disposition of 1,225 common shares on March 15, 2026, to cover tax liabilities from RSU vesting.

Summary

• Zhou Rong, Senior EVP, Production Center at Amphastar Pharmaceuticals, Inc. (AMPH), reported a planned disposition of common stock.
• On March 15, 2026, 1,225 shares of common stock are scheduled to be withheld.
• This disposition is to satisfy tax liabilities associated with the vesting of restricted stock units (RSUs).
• The shares were valued at $18.18 for this transaction.
• The transaction is part of a pre-arranged Rule 10b5-1(c) plan, as indicated by the checked box.
• Following this transaction, Zhou Rong will directly own 171,554 shares and indirectly own 99,668 shares through the Zhou Family Trust and 5,000 shares through a spouse.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, representing a routine administrative transaction related to executive compensation and tax obligations, with no direct implications for the company's operational or financial performance.

Positives

• The transaction is a routine tax withholding, indicating the vesting of Restricted Stock Units (RSUs), which is a form of executive compensation.
• The transaction is pre-planned under Rule 10b5-1(c), demonstrating a structured and compliant approach to insider trading.

Negatives

• A disposition of shares, even for tax purposes, results in a reduction of the insider's direct ownership stake in the company.

Future Outlook

No specific forward-looking statements or guidance are provided in this filing beyond the scheduled transaction date.

Industry Context

StockSavvy.ai notes that routine insider transactions, such as tax-related dispositions of shares from RSU vesting, are common across the pharmaceutical industry as part of executive compensation packages. These transactions typically do not signal a change in company fundamentals or strategic direction.

Comparison to Industry Standards

• This type of tax-related share withholding is a standard practice for executives receiving equity compensation across all industries, including pharmaceuticals.
• It aligns with typical compensation structures seen at comparable companies like Pfizer, Johnson & Johnson, or Merck, where RSUs are a significant component of executive pay.
• The specific number of shares disposed is relatively small compared to the company's overall market capitalization and the executive's total holdings, making it a routine event.

Stakeholder Impact

• Shareholders: Minimal impact, as it's a routine, small-scale disposition for tax purposes by an executive.
• Employees: No direct impact.
• Management: Routine tax obligation fulfillment for an executive.

Key Dates

Recommendation

This Form 4 reports a routine, pre-scheduled disposition of a relatively small number of shares by an executive to cover tax liabilities from RSU vesting. It does not indicate any change in the company's fundamentals, strategic direction, or the executive's confidence in the company. Therefore, it provides no new information that would warrant a change in investment recommendation.

Keywords

Amphastar Pharmaceuticals, AMPH, Zhou Rong, Form 4, insider trading, stock disposition, tax withholding, RSU vesting, Rule 10b5-1, executive compensation